Loading...
Docoh

Kezar Life Sciences (KZR)

Utility
CDP protein secretion inhibitors
24 May 22
Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61.
Dustin McMinn, John William Taunton, Phillip Patrick Sharp
Filed: 29 Mar 19
Utility
Immunoproteasome Inhibitor Formulations
10 Feb 22
Provided herein are pharmaceutical formulations comprising KZR-616 or a salt thereof, and a sugar, wherein the formulations are lyophilized, methods of preparing said formulations, methods of treating immune-related diseases, and methods of treating inflammation.
Evan Lewis
Filed: 4 Oct 19
Utility
Immunoproteasome Inhibitors and Immunosuppressive Agent In the Treatment of Autoimmune Disorders
6 May 21
Provided herein are methods of treating autoimmune diseases comprising administering to a subject suffering therefrom an immunoproteasome inhibitor and an immunosuppressive agent.
Tony Muchamuel
Filed: 23 Aug 18
Utility
Triazacyclododecansulfonamide ("Tcd")-based Protein Secretion Inhibitors
18 Mar 21
Henry Johnson
Filed: 15 Mar 19
Utility
Crystalline Salts of Peptide Epoxyketone Immunoproteasome Inhibitor
4 Feb 21
Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.
Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
Filed: 9 Oct 20
Utility
CDP Protein Secretion Inhibitors
21 Jan 21
Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61.
Dustin McMinn, John William Taunton, Phillip Patrick Sharp
Filed: 29 Mar 19
Utility
Crystalline salts of peptide epoxyketone immunoproteasome inhibitor
16 Nov 20
Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
Filed: 28 Jun 17
Utility
Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
21 Sep 20
Henry Johnson, Sean Dalziel, Dustin McMinn
Filed: 28 Jun 17
Utility
Combination Therapy for Immunological Diseases
2 Sep 20
Provided herein are methods of treating immune-related disorders comprising administering to a patient suffering from the disorder a therapeutically effective amount of a LMP2-selective inhibitor and a therapeutically effective amount of a LMP7-selective inhibitor.
Dustin McMinn, Tony Muchamuel, Henry Johnson, Eric Lowe, Janet Anderl
Filed: 20 Sep 18
Utility
Crystalline Salts of Peptide Epoxyketone Immunoproteasome Inhibitor
9 Oct 19
Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
Filed: 28 Jun 17
  • 1
Patents are sorted by USPTO publication date, most recent first